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on beaches in Puerto Rico and Miami; 
swimming pools in Sydney, Australia; 
and jogging paths along the Charles 
River in Boston, we learned a great deal 
about the ideal ingredients, vehicles, 
application methods, and sweat and 
water resistance of sun protection for-
mulations. I saw research findings rap-
idly influence commercial products 
and consumer practices. Fitzpatrick 
was among the first and most vocal 
missionaries espousing the importance 
of sun protection. Working with Franz 
Greiter of Switzerland, we developed 
the sun-protection-factor concept.
Fitzpatrick’s major interest at the time 
was vitiligo, for which he advocated 
treatment with oral 8-methoxypsoralen 
and subsequent exposure to sunlight. 
I used lasers, monochrometers, and 
other instruments to determine the 
time course and action spectrum for 
psoralen-induced skin phototoxicity. 
I ingested the drug myself, and then at 
various times I exposed postage stamp–
sized areas of my skin to many different 
fluences of UVA. I measured the peak 
skin redness at multiple times after 
exposure, making observations every 
Learning the ropes (1970–1974)
I am almost the same age as the 
Journal of Investigative Dermatology. 
I had the privilege of knowing all the 
founders of the Society for Investigative 
Dermatology and collaborated with 
two of them (I. Blank and T. Fitzpatrick) 
for decades. I began my research 
career in 1970 as an apprentice to 
Thomas B. Fitzpatrick, chairman of the 
Harvard Medical School Department 
of Dermatology and chief of dermatol-
ogy at Massachusetts General Hospital. 
Arguably true, he considered himself 
the most influential dermatologist in the 
world. I assisted him in his research on 
skin pigmentation and in the develop-
ment of sunscreens and accompanied 
him as a Sherpa in his global travels.
According to the US Bureau of 
Weather, Arizona has the most predict-
ably cloudless sky in North America. 
At least once each summer during 
my residency training, Dr. Fitzpatrick, 
his assistants, and I spent a week at 
Arizona State Prison quantifying the 
effect of sunscreens on the backs of 
prisoners lying in the sun. Through 
these and additional studies conducted 
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Dermatology is the study of skin and all its content and research has no bound-
aries. Clinical dermatology and cutaneous photobiology provided me with rich 
training to learn the joy and agony of translational research. Using that experi-
ence, I initiated three experiments to test various theories, methodologies, and 
environments for the support of hospital-based interdisciplinary translational 
research.
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four hours, day and night. By doing this 
twice a week for several months and 
covering my entire shin surface with 
pigmented squares labeled with ink, 
I determined the most effective timing 
and exposure parameters.
I convinced physicists from GTE 
Sylvania to develop a novel UVA 
source capable of activating psoralen 
over large areas of skin, making the 
treatment of vitiligo safer, more con-
venient, and available year-round. 
However, it still required many months 
of twice-weekly trips to the large spe-
cial UVA source, and treatment was 
not always very effective. The contribu-
tions to dermatology were limited, but 
several subsequent events led to a huge 
impact.
John Voorhees and his colleagues at 
the University of Michigan observed 
improvement in a small plaque of pso-
riasis after topical application of pso-
ralen and subsequent exposure to UVA 
from a small handheld device. GTE 
Sylvania developed an improved UVA 
source, a booth that made it possible to 
safely deliver uniform amounts of radi-
ation to large skin surfaces. Klaus Wolf, 
professor of dermatology in Vienna and 
a disciple of Fitzpatrick, suggested that 
we try the new treatment on patients 
with widespread disfiguring psoriasis. 
Most importantly, Mr. M. walked into 
our clinic.
Mr. M. was a 45-year-old unem-
ployed, uninsured, homeless alcoholic. 
He was covered from head to toe with 
red, raw, scaling disfiguring psoriasis. 
He looked like a red monster constantly 
shedding sheets of scales, which hung 
like dirty snow to his ragged clothing. 
Mr. M. agreed to have one half of his 
body treated with our recently devel-
oped method for treating vitiligo. We 
hospitalized him in order to observe 
him carefully and because he had no 
place to go. Because of his appearance, 
he was shunned by shelters and by his 
fellow homeless men and women who 
slept under the bridges. No one ques-
tioned the necessity of this admission 
or how it would be paid for.
Two hours after Mr. M. ingested 40 
mg of 8-methoxypsoralen (the time 
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of peak photosensitization I had so 
laboriously determined), I carefully 
shielded his genitals and the entire 
left side of his body with sheets and 
exposed his right side in our new UVA 
booth. After eight treatments given 
every other day, Mr. M.’s right side 
looked entirely normal and nicely 
tanned. There was no evidence of pso-
riasis. We then treated the left side, 
with the same gratifying result. One 
day, Mr. M. left the hospital without 
permission, got drunk, and, a very 
happy man, slept in Boston’s best 
shelter for the homeless.
Although I was very excited by Mr. 
M.’s magical response to treatment, 
Fitzpatrick insisted on silence. In 
secret, we hospitalized and treated 
21 additional patients with the same 
results. Using his prestige and con-
nections, Fitzpatrick arranged for 
the new treatment to be announced 
simultaneously on the front page 
of the New York Times, as the lead 
article in the New England Journal of 
Medicine, and to thousands of derma-
tologists during the plenary session 
of the 1972 meeting of the American 
Academy of Dermatology (AAD). We 
called the treatment PUVA (psoralen 
plus UVA) and became the buzz of the 
dermatology world, with some declar-
ing us to be frauds and others wanting 
to get their hands on the treatment as 
soon as possible. Subsequent studies 
showed that this treatment was also 
effective in many other skin disorders, 
including severe eczema of the palms 
and soles, atopic dermatitis, poly-
morphous light eruption (PMLE), and 
cutaneous T-cell lymphoma.
Widespread use of PUVA would 
require third-party reimbursement, 
unlikely without approval of the 
treatment by the US Food and Drug 
Administration. The process for approv-
al of a new drug or a new use for an 
approved drug was expensive, tortur-
ous, and unpredictable. Approval for 
devices was less burdensome, but it 
was controlled by a separate group 
within the FDA. Our new treatment 
for psoriasis involved both a drug and 
a device, making the approval process 
very complex. 8-methoxy psoralen was 
produced by a very small company 
supplying just enough drug for the 
small, stable vitiligo market. The FDA-
required animal toxicity studies and 
clinical trials with vitiligo patients were 
dated and inadequate. Testing efficacy 
of PUVA in animals was impossible 
because there were no animal models 
for psoriasis. There was well-founded 
concern that PUVA could cause skin 
cancer. Because UVA is absorbed by 
the ocular lens and psoralen from the 
bloodstream entered the eye, there 
was a theoretical threat that repeated 
use of PUVA could lead to cataracts. 
I asked, but the pharmaceutical com-
pany had no interest in supporting 
multicenter clinical trials with humans 
or even completing the paperwork 
to seek approval for a new psoralen 
indication. At best, the light source 
provided by GTE Sylvania was a hand-
made prototype, and the company had 
no experience (and, as it turned out, 
very little interest) in going into health 
care. To make things worse, we had not 
obtained FDA approval, written patient 
consent, or institutional approvals 
for the experimental treatment of the 
patients we had already treated.
I personally took on the daunt-
ing responsibility of seeking FDA 
approval. The results presented at the 
AAD meeting were so convincing that 
hundreds of dermatologists and 20 
medical centers asked how they could 
start using the treatment. We selected 
14 academic centers in addition 
to Massachusetts General Hospital 
(MGH) and said that they could use 
PUVA on the condition that each con-
duct a careful clinical trial with at 
least 50 psoriasis patients, at their own 
expense. I convinced GTE Sylvania to 
build 16 (2 for me) chambers the size 
of a telephone booth, with the inner 
surface lined entirely with vertical, 
side-by-side, five-foot fluorescent 
UVA bulbs. GTE Sylvania also agreed 
to convert one of their large build-
ings into an animal research facil-
ity and pay for the required animal 
testing. I approached ophthalmolo-
gists based at Massachusetts Eye and 
Ear Infirmary and Harvard Medical 
School who were eager to volunteer 
their time to participate in the larg-
est cataract study ever attempted. 
The subjects were hundreds of New 
Zealand rabbits.
After another 91 patients were 
treated independently in Europe, the 
FDA approved the largest clinical study 
ever done in dermatology. Supervised 
by Rob Stern, more than 1,400 patients 
at 14 medical centers were followed 
for 30 years. The National Institutes of 
Health (NIH) provided a grant to sup-
port a registry of treatment parameters 
and support epidemiologists and stat-
isticians to analyze and interpret the 
data. After several hearings, the FDA 
approved PUVA. GTE Sylvania elected 
not to enter the medical marketplace, 
and within weeks several companies 
in Europe and the United States began 
manufacturing devices to expose small 
or large areas of the skin of sitting, 
standing or supine patients to UVA. 
For the next two decades, PUVA was 
the worldwide treatment of choice for 
severe psoriasis.
One of the volunteers we treated 
was a striking regal, perfectly propor-
tioned blonde whose second multimil-
lionaire husband was Arthur Wellman, 
made rich and powerful in the wool 
industry. After giving his business to 
his sons, he entertained himself by 
becoming a “wildcat” oil driller, mak-
ing more fortunes. His brother, “Wild 
Bill” Wellman, was a Hollywood 
movie producer. Both Wellman broth-
ers were bigger than life.
As an adult, Mrs. Wellman devel-
oped generalized disfiguring psoriasis, 
worst on her face, arms, and hands—a 
psychosocial disaster for her. She had 
failed to respond to multiple treatment 
regimes. After 10 PUVA treatments, she 
looked normal and tan. In gratitude, 
Mr. Wellman contributed $75,000 to 
my research to buy some much-needed 
equipment. I kept him informed about 
the progress of our work and began vis-
iting him and his wife in Palm Beach. 
His crew of three would serve lunch as 
I presented research updates aboard his 
yacht. I provided an office in my lab for 
Mr. Wellman and he often spent two or 
three days at a time in Boston, thinking 
of himself as my partner. By the time 
he had donated over a million dollars, 
I had moved to new research space at 
MGH, and in 1975 I named my group 
the MGH–Wellman Laboratories of 
Photomedicine (later to be called the 
Wellman Center).
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a brief time of independent research 
(1975–1987)
Stimulated by challenges that were 
entirely clinical, I spent 12 years 
(1975–1987) conducting research that 
was simple and descriptive. During 
that time, the Society for Investigative 
Dermatology and JID communities 
provided me the major platform from 
which to learn from my colleagues.
During these years, one-third of 128 
original contributions were published 
in the JID, and in one year (1985) all 
publications were in the JID (Figure 1).
There was a five-year period when 
practically every psoriatic patient com-
ing to MGH participated in a massive 
outpatient clinical study as we made 
many incremental changes to the 
PUVA and UVB treatment of psoriasis. 
Because we used bilateral-comparison 
methodology, patients had longer stays 
in the treatment units, longer courses 
of treatment, and more frequent visits. 
We kept all the patients informed about 
what we learned.
The Harvard Medical School derma-
tology trainees and several of the MGH 
dermatology faculty joined in. We 
made careful diagrams of the extent 
of psoriasis and amount of scaling and 
redness and took thousands of pictures. 
Most patients volunteered to come to a 
free Saturday-morning clinic where my 
trainees helped me make side-by-side 
comparisons and evaluate progress. 
Although we scheduled the patients 
so that they would not have to wait to 
be seen, they started coming early and 
staying late, spending hours in our con-
ference room commiserating with each 
other about the life of a psoriatic and 
sharing treatment stories, often show-
ing how their left arm differed from 
their right arm and, if the study was 
blinded, guessing which treatment 
was used on which side of their body. 
When the three- to four-hour clinic was 
over, many patients stayed behind and 
I would lecture about psoriasis, present 
our results to date, and answer ques-
tions. They began bringing lunches and 
developed a large chat group.
We treated (studied) 471 patients 
and published 17 papers to share the 
results with dermatology worldwide. I 
never obtained written consent or filled 
out any hospital forms; no institutional 
review board critiqued our protocols. 
No patient ever complained. Patients 
were pleased to participate, and many 
stayed in touch with me for years after I 
stopped seeing patients.
While these research activities domi-
nated our outpatient clinics, I converted 
our 15-bed dermatology inpatient ser-
vice at MGH into a research center to 
study the “Goeckerman treatment” 
empirically used widely since the 
1920s to treat severe, disfiguring pso-
riasis. Because this treatment required 
total-body application of sticky, messy, 
strong-smelling crude coal tar, the 
Goeckerman regimen was usually 
confined to specialized inpatient areas 
or treatment facilities. Once or twice 
each day, a nurse applied crude coal 
tar to all skin surfaces and wrapped the 
patient in gauze or sheets, after which 
the patient sat on the ward or remained 
in bed all day. Once each day, the 
patient bathed in a tub with water laced 
with special powders and subsequently 
exposed his or her body to large UVB 
sources. The goal was to vary the UVB 
exposure time to cause mild redness 
but not lead to a painful burn. After 
three to five weeks in the hospital, most 
patients were largely free of psoriasis.
I decided to study each compo-
nent of the Goeckerman treatment. 
Elaborate, time-consuming methods 
were developed to keep the coal tar 
ointment from contaminating the “no-
tar” side or to shield the “no-UVB” 
side from exposure in the treatment 
units. An army of nurses and assistants 
and family members used sheets and 
reams of tape to treat—or not treat—
with every possible combination of tar, 
ointment, or UVB. When we found that 
one side of the body responded better 
than the other, we would record our 
results and treat the whole body with 
the superior regime. This sometimes 
led to an additional 5 to 10 days in the 
hospital. The patients loved it. There 
was constant chatter and even betting 
on “winning” sides. Many chairs were 
permanently ruined by tar because the 
patients would visit one another or 
have chat groups in the hallway.
Our results were very interesting. The 
Goeckerman treatment was certainly 
effective. We were the most recent of 
many groups who, over four decades, 
demonstrated this. But we were surprised 
to learn that the crude coal tar and the 
sticky ointment in which it was mixed 
were not needed. A thin layer of oint-
ment or mineral oil applied immediately 
before UVB exposure altered the optical 
properties of the plaques of psoriasis and 
resulted in more effective phototherapy. 
Within two years, most inpatient derma-
tology units worldwide were closed, just 
ahead of the economic crunch affecting 
inpatient treatment days.
I used our growing collection of 
optical equipment to determine the 
exact action spectrum for UV treat-
ment of psoriasis. After showing that 
UVA alone was therapeutic, we found 
that even at daily exposure doses up 
Figure 1. Parrish publications, 1975–1987.
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to 50 times minimal erythema dose, 
wavelengths shorter than 290 nm 
were not therapeutic. However, mono-
chromatic sources at 300, 304, and 
313 nm cleared plaques with fewer 
exposures and at lower cumulative 
doses than did broad-spectrum UVB. 
Surprisingly, the studies suggested 
that wavelengths shorter than 290 nm 
may be proliferogenic, diminishing the 
therapeutic effect of the 300-, 304-, 
and 313-nm radiation. These observa-
tions led to the development of “nar-
row-band UVB” to treat psoriasis and 
other skin disorders.
The equipment we gathered to study 
psoriasis also allowed me to determine 
the action spectrum for tanning. Again, 
hundreds of small squares on the back 
or buttocks of normal volunteers were 
exposed to various wavelengths and 
doses of narrow bands of UVR. In fair-
skinned subjects, the action spectrum 
for tanning did not differ significantly 
from that for erythema. However, in 
subjects who were capable of tanning, 
we were delighted to observe that the 
action spectrum differed slightly but 
significantly from that for erythema. In 
some subjects, a single exposure less 
than one-third minimal erythema dose 
led to delayed pigmentation response. 
This “tan-without-burn” possibil-
ity helped launch the tanning industry. 
Because UVA was the tan-without-
burn component of the UVR spectrum, 
the technology for producing high-
intensity UVA improved and became 
widely available. The tanning mar-
ket was hugely more profitable than 
the medical market. Although I was 
presented with several opportunities 
to be rich and famous (or infamous, in 
the eyes of my fellow academicians), 
I elected to distance myself from the 
tanning business because I didn’t want 
to be distracted from my research and 
because I knew from my own work 
that tanning was probably a DNA-
damage response.
I had great fun taking side trips 
using the scenic route. Combination 
therapies. Photodynamic therapy. 
Oxygen dependence of UVA-induced 
erythema. Action spectrum for vita-
min D photosynthesis. Expanding the 
spectrum of sunscreens into UVC and 
UVA. Action spectra for sunburn cells, 
in vivo DNA damage, desquamation. 
With Warwick Morison, a member of 
my growing research team from years 6 
to 10, we demonstrated and explained 
a number of local and systemic effects 
of UVR and PUVA on the immune sys-
tems of animals and human volunteers.
the first-born academic son
As I adopted Mr. Wellman as my new 
father figure, I also adopted an aca-
demic son. When I met Rox Anderson, 
he was a Massachusetts Institute of 
Technology graduate who had hap-
pily dropped out of mainstream busi-
ness and academic tracks. He spent 
his summers in the woods directing a 
camp for troubled boys. In the winter, 
he was the secretary to the chaplain at 
Wellesley College, an all-girls school. 
His flower-child, free-love wife and my 
wife were members of a feminist book 
club. Out of curiosity, Rox and I went 
to one meeting to listen from the back 
of the room. I hired him that night as a 
research technician and he began work 
in my lab the next day.
Over 10 years, Rox transitioned 
from being my technician and stu-
dent to being my coinvestigator and 
teacher. Collaborating with Rox was 
among the greatest joys of my life. We 
spent hours at the blackboard think-
ing about the fascinating intersections 
among photons, biochemistry, physiol-
ogy, and skin. The optical “therapeutic 
window” in skin. Mechanism of laser 
ablation and photoacoustic injury. 
Photoaddition. Photoaugmentation. 
Based entirely on the microanatomy 
of capillary hemangiomas and our 
growing understanding of the effects 
of lasers on skin, Rox hypothesized the 
ideal properties of a laser that could 
remove port wine stains without scar-
ring, a feat never before possible. 
Because no such laser existed, we con-
vinced a budding laser manufacturer 
to build one in his garage. The tunable 
dye laser worked, and we called the 
approach selective photothermolysis.
Using my lab as his home base, Rox 
continued his research while complet-
ing medical school, an internship, 
and dermatology specialty training at 
Harvard Medical School. Dermatology 
changed forever as Rox developed uses 
of lasers for safe removal of tattoos, 
hair, pigmented birthmarks, wrinkles, 
and dilated blood vessels.
Global response
The explosive impact of PUVA and 
UVB treatments and the rapid adop-
tion of lasers in the clinical practice 
of dermatology pulled me into global 
travel as a lecturer, visiting professor, 
consultant, panelist, keynote speaker, 
and special guest. For several years 
I was out of Boston 40 to 50% of the 
time. With my first NIH grant, a grant 
from the Department of Energy, and Mr. 
Wellman’s donations, by 1987 I was 
able to support a research group of 10 
people, including 3 faculty members. 
My own independent research required 
little or no funding.
In the 1970s and 1980s, I tackled 
every barrier in the complex journey 
from idea or research observation to 
the establishment of “best practice” in 
dermatology. Firsthand, I learned how 
difficult it is to perform translational 
research. The many required skills are 
not often present in a single investi-
gator, and most academic teaching 
hospitals do not have the resources to 
facilitate each of the steps needed for 
clinical implementation.
The rules, regulations, and over-
sight of research began to change and 
I began to feel buried in bureaucracy 
and paperwork. Today, many of the 
components of my research, such as 
use of prisoners, using oneself as a sub-
ject, and treating single subjects with 
split therapy, would be considered 
inappropriate or illegal.
In 1987, as I learned more about the 
growing number and magnitude of the 
institutional, regulatory, cultural, fiscal, 
and legal complexities and compliance 
issues, I gave up all personal claims to 
authorship, intellectual property rights, 
and direction of individual projects in 
order to explore the factors that enabled 
multidisciplinary translational research 
in an academic medical center.
three experiments
1. mGH Wellman center of Photo-
medicine (WcP; http://www.massgen-
eral.org/Wellman), founded in 1975. 
The task of developing the WCP into a 
multidisciplinary translational-research 
center was made somewhat easier 
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because we worked with only one tech-
nology: photonics. We accumulated 
lasers and other sophisticated sources 
of energy, and I recruited physicists, 
chemists, engineers, and biologists with 
training and expertise related to UV, vis-
ible, and near-infrared regions of the 
electromagnetic spectrum. I insisted 
that all projects be led by a physician 
even if he or she had very little research 
experience. We provided the remain-
der of a multidisciplinary team, equip-
ment, technical help, industry partners, 
and funding for the team led by what I 
called a “C-4” (competent, committed 
clinical champion).
In 1983, about the time of Mr. 
Wellman’s death, President Reagan 
challenged the scientific community 
to design a shield that could protect 
the United States against rockets car-
rying nuclear weapons. His Strategic 
Defense Initiative, nicknamed “Star 
Wars,” was politically fraught with 
problems and technically not likely to 
work. The system had to work perfectly 
the first time because there was no way 
to test it. Nonetheless, $30 billion was 
poured into Star Wars over the next 
10 years to develop a vast network of 
sensing devices, small laser “guns,” and 
guided missiles.
One of the most unrealistic fanta-
sies included shooting down incom-
ing nuclear missiles with space-based 
lasers. In a remarkable sell, the inven-
tors of a new laser called the free-elec-
tron laser (FEL) convinced a bevy of 
congressmen and military leaders that 
the FEL was the technology needed for 
the success of Star Wars. Subsequently, 
the inventor and his colleagues per-
suaded the parties responsible for Star 
Wars that the unique properties of the 
FEL were also ideal for medical appli-
cations. Hundreds of millions of dol-
lars were funneled to medical research, 
partly because of this unfounded hope 
and partly to increase the popularity of 
the Star Wars program.
The properties of the FEL that caused 
excitement among biologists (physicists 
were already familiar with the proper-
ties) were the wavelength tunability 
throughout the UV, visible, and near-
infrared spectrum and the power (if 
focused over small targets exceeding 
that of the surface of the sun). Much 
less attention had been paid to the very 
short duration (10-6 to 10-12 seconds) of 
the laser pulse and the very high peak 
power. The FEL was one of a growing 
number of “high peak power–short 
pulse” (HPP-SP) lasers.
As an expert witness, I was invited 
by Congress to predict medical uses of 
the FEL. No one was interested in my 
opinion about the impracticality of the 
role of the FEL in shooting down mis-
siles from space. However, I got the 
panel’s attention when I stated that, for 
at least the next 20 years, there would 
be no medical or surgical applications 
of an FEL. I added four caveats. First, 
for the past 10 years and possibly the 
next 10 years, the most novel and medi-
cally useful applications of lasers would 
result from HPP-SP radiation generated 
by lasers or other devices. Second, we 
knew very little about the physics and 
biological response to HPP-SP lasers. 
Third, the FEL might possibly advance 
HPP-SP laser medical research. Fourth, 
however, the FEL would most likely 
never be used in health care because 
it was too large, expensive, unreliable, 
complex, and dangerous. If FEL research 
led to new surgical applications of HPP-
SP therapies, smaller, less expensive, 
dedicated lasers would be designed 
to exploit the novel applications. The 
panel of politicians and scientists asked 
whether I would be willing to study the 
effects of HPP-SP lasers on tissue.
Over the next 20 years, the Medical 
FEL (MFEL) Program provided me with 
funding to study the biological effects 
of HPP-SP lasers on tissue. Four other 
medical centers were also selected for 
funding. One was Stanford, the site 
of the invention of the FEL. The other 
three agreed to install FELs within two 
years (if they could actually be built). I 
did not agree to house an FEL, which 
at the time was as big as a small loco-
motive, required a cyclotron as the 
energy source, needed to be in a room 
shielded by two feet of concrete and 
lead, and required two physicists or 
engineers to turn it on (which could 
be done about 20% of the time). Only 
after three years of research on HPP-SP 
effects was I required to actually use an 
FEL to continue my research. Several 
other university sites agreed to either 
build biology labs next to existing FEL 
research facilities or place an FEL in 
a medical–surgical facility. Although 
we could not think of an interesting, 
important, or practical experiment, 
I agreed to periodically send a team 
to do research with an existing MFEL. 
Because of the inability to turn on 
the laser, most trips were canceled or 
my team waited for days to get some 
“beam time.”
Five years into the MFEL Program, all 
funded centers were required to house 
an FEL and competition was opened to 
other academic centers. I convinced the 
leadership and the trustees of MGH to 
fund a team of architects and engineers 
to find a possible location for an FEL. 
The only practical location was a two-
story bunker underneath the Bulfinch 
lawn in front of the original MGH, built 
in 1848 and now a national historical 
landmark. This would require tearing up 
most of the lawn and months of work. 
The laser beam would be conducted 
with special mirrors into my lab on the 
second floor of a nearby building. The 
trustees allowed me to compete for the 
site and subsequently install an FEL if 
we were to be chosen. I made sure that 
the funding we requested was at least 
four times that proposed by any other 
medical center. Although we were 
not chosen as an FEL site, our work 
was supported for another 15 years. 
Recently, FEL technology has advanced 
to the extent that Rox and colleagues 
at the Jefferson National Accelerator 
Facility used the FEL there to show that 
certain wavelengths can selectively 
affect lipid-rich tissues such as fat and 
sebaceous glands. As I predicted long 
ago, the FEL itself is not practical, but 
in this case it will probably spawn new 
medical lasers.
The WCP grew to be a large multi-
disciplinary group studying the effects 
of optical, infrared, and UV radiation 
on biological materials and living tis-
sue. Our growing understanding of 
HPP-SP effects led to many new diag-
nostics and treatments, with a substan-
tial impact on health care. Our group 
introduced the use of lasers to break 
up kidney stones and contributed 
more than 20 FDA-approved optical 
diagnostics and treatments. We laid 
the research foundation for many of 
the surgical uses of lasers. We never 
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obtained an FEL, but the MFEL Program 
provided well over $100 million to 
support our research.
WCP faculty growth was a direct 
reflection of my ignorance. Whenever 
expertise was needed in a specific topic 
(photochemistry, laser physics, immu-
nology, optics, cell biology), I would 
recruit a specialist to join the WCP. All 
projects were led by a C-4. Today (year 
36), WCP has a staff of 170, including 4 
professors and 9 associate professors, a 
$20 million per year research program, 
32 NIH grants, and royalty income 
exceeding $6 million per year. WCP 
leads the world in the development of 
biomedical optics, in vivo microscopy, 
and the use of lasers in medicine and 
surgery. Many of the approximately 85 
publications per year are prominently 
profiled in the top journals of many 
different medical specialties. Under 
the leadership of Rox Anderson and a 
growing number of superstar investiga-
tors, the WCP will be vibrant and pro-
ductive for decades to come.
2. mGH–Harvard cutaneous Biology 
research center (cBrc; http://www.
massgeneral.org/cbrc), founded in 
1989. Although not trained in the 
fundamental principles of molecular 
biology, cell biology, or biochemistry 
and never having done basic bench-
top research, I proposed to the leader-
ship of Shiseido, a Japanese cosmetics 
company, that I form an MGH-based 
research group at the cost of $10 mil-
lion a year to study the fundamentals 
of skin biology. In a six month period, 
I made eight trips to Tokyo, two to 
California, one to Hawaii, and three 
to New York. Shiseido agreed and 
I founded and directed the MGH–
Harvard CBRC. I presented a five-part 
hypothesis that the Shiseido leadership, 
the MGH leadership, and all future 
CBRC investigators agreed to accept—
or at least to test:
 1.  Starting with space and money 
but no track record or existing 
faculty, the CBRC could attract 
excellent investigators from the 
leading edges of science.
 2.  By living in the CBRC 
environment with appropriate 
leadership, these new invest i gators 
would collaborate extensively, 
making the whole greater than 
the sum of the parts.
 3.  If dermatologists were among 
the investigators and the CBRC 
was embedded in the dermatol-
ogy department, skin biology 
would become a dominant 
theme integrating the multidisci-
plinary research.
 4.  Good ideas for skin care prod-
ucts would percolate up from 
the CBRC.
5.  Shiseido would be able to rec-
ognize and capture those ideas 
and take novel products to the 
marketplace.
Suddenly, I could recruit 8 to 10 new 
investigators. I chose not to recruit from 
the pool of investigators in existing aca-
demic dermatology laboratories, but 
instead to recruit the best investigators I 
could find at cutting edges of research. 
Massachusetts Senator Ted Kennedy 
and James Wyngaarden, director of the 
NIH, helped to mitigate the political 
concerns of “brain drain,” a hot topic at 
the time.
The CBRC grew to be a 120-person 
laboratory, the largest basic-science 
skin research laboratory in the world. 
The CBRC produced many high-qual-
ity publications, launched careers, 
made important scientific observations, 
raised the level of research in cutane-
ous biology, and sparked three new 
product lines for Shiseido.
I predicted it would take five years to 
demonstrate sequentially powerful evi-
dence to support the five-part hypoth-
esis and that success would be of such 
magnitude that the CBRC would be 
the model for industry–academia part-
nerships. My ambition exceeded my 
ability to deliver an enduring sustain-
able model in the changing academic 
and industry research environment. 
After more than 20 years, the endur-
ing impact of each step of the five-
part hypothesis was successively less 
impressive than the preceding step. 
I was not a subject-matter expert and 
may not have made recruiting and 
retention decisions that optimized the 
group dynamics necessary to sustain 
the lofty vision. Shiseido invested more 
than $200 million and then, as times 
changed, markedly reduced support.
Now in year 23, the CBRC is an 
excellent academic laboratory with 
a faculty and staff of 82 persons and 
an annual budget of $13 million; 12 
senior and 12 junior faculty have 29 
NIH grants. Under the leadership 
of David Fisher, the CBRC has con-
structed a unique high-throughput 
small-molecule screening program 
specifically designed for the discov-
ery of novel topical small molecules 
for cutaneous applications. The small-
molecule libraries currently available 
include tailored lipophilic synthetic 
compounds and one of the world’s 
largest collections of natural product 
extracts. The CBRC faculty manifest 
expertise in design, implementation, 
and validation of assays relating to 
nearly all aspects of skin health and 
disease. Other CBRC faculty are 
experts in signaling, transcription, 
development, and pathology of skin. 
They utilize numerous model organ-
isms from drosophila to humans, 
including the active development of 
novel in vivo technologies such as in 
vivo knockdown and topical small 
interfering RNA approaches.
3. center for Integration of medicine 
& Innovative technology (cImIt; 
http://www.cimit.org), founded in 
1999. During the 1970s and 1980s, 
there were huge advances in the tech-
nologies serving consumer markets, 
manufacturing industries, and nation-
al-defense needs. Yet the migration of 
those technologies toward health-care 
needs was slow, stymied by the diffi-
culties of collaboration between those 
who knew the clinical issues well and 
those who knew available technolo-
gies well, as well as by highly com-
plex regulatory and reimbursement 
hurdles. There were major challenges 
to multidisciplinary engineering–bio-
medical collaboration and to the 
translation of research and new ideas 
into patient care. Peer-review fund-
ing processes had devolved to a low-
risk mindset, leaving early-stage ideas 
lacking support for proof of concept. 
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Multidisciplinary and interdisciplinary 
collaborative work was not adequately 
rewarded by traditional granting mech-
anisms and academic promotion pro-
cesses. New concepts often ended at 
the publication stage, satisfying only 
the academic imperative. Technology 
development and implementation 
required skills disjointed from those 
of typical clinicians or biomedical 
researchers. Navigating regulatory-
approval and reimbursement pathways 
required the collaboration of yet anoth-
er set of professionals, and a structured 
approach was needed to connect 
innovators with the needed expertise.
Collaborating with several young 
physicians and my long-time colleague, 
Ron Newbower, CIMIT was organized 
to address this siloed nature of research, 
the need to rapidly translate research 
into clinical practice, and the belief in 
the power of multidisciplinary collabora-
tion. It has grown to encompass 13 of the 
premier clinical, research, and academic 
institutions in the greater Boston area 
(Table 1). Critical collaboration and 
support have been provided by the 
Department of Defense, which recog-
nized the value CIMIT could bring to the 
care of those who serve in combat.
In all clinical specialties, within the 
domain of devices, procedures, and 
clinical systems engineering, CIMIT acts 
as a “center without walls” and serves 
as a portal to Boston’s world-class medi-
cal and scientific communities. It can 
quickly mobilize teams of clinicians 
and scientists with complementary 
expertise drawn from anywhere across 
Boston’s diverse health-care, technol-
ogy, entrepreneurial, and corporate 
organizations to engage and focus their 
collective creativity and capabilities on 
current health-care challenges. CIMIT 
is not designed to fund basic research. 
Rather, it invests in accelerating the 
implementation of technological 
innovation and development of human 
capital to drive the cycle of innovation.
The CIMIT process aims to “find, 
fund, and facilitate” investigators who 
have novel ideas for solving unmet 
clinical needs. CIMIT engages “site 
miners,” based at each of CIMIT’s 
consortium institutions, who report 
to the institution’s CEO/president. 
Site miners are senior members of the 
research and clinical community who 
are actively engaged in identifying 
clinicians and scientists with creative 
ideas that might gain traction in the 
CIMIT model. Each year CIMIT’s call 
for proposals for its Innovation Grant 
program generates hundreds of inno-
vative approaches to improving health 
care from across the consortium. In 
2011, discussions led to more than 
300 teams submitting two-page pre-
proposals describing their ideas and 
potential clinical impact. About half 
were asked for more detailed propos-
als; typically, about one-third of these 
are selected to receive initial funding 
and facilitation support from CIMIT. 
CIMIT’s full-time faculty provide indi-
vidualized guidance through the chal-
lenges related to intellectual property, 
institutional compliance, regulatory 
affairs, clinical implementation, and 
commercialization.
In an effort to quantify, study, and 
improve its methodology, CIMIT con-
ducted a comprehensive self-assess-
ment in 2009 that examined the inputs 
and outcomes of 362 separate proj-
ects, representing 117 distinct project 
clusters that CIMIT supported between 
1998 and 2006. The accumulated col-
lection of publications, project reports, 
grant submissions, personal narratives, 
and experiences with clinical adoption 
and/or commercialization of products 
proved to represent a wealth of insights 
to help evaluate and improve the over-
all CIMIT model. The key output met-
rics included the following:
1.  Clinical adoption: more than 
20% of project clusters have 
achieved approval for human use.
2.  Commercialization: more than 
30% have been licensed to an 
established company or enabled 
a start-up company.
table 1. overview of the center for Integration of medicine  
& Innovative technology (cImIt)
consortium institutions Strategic initiatives and programs
Massachusetts General Hospitala Neurohealth
Brigham & Women’s Hospitala  Neurotechnology
Charles Stark Draper Laboratorya  Traumatic brain injury
Massachusetts Institute of Technologya  Post-traumatic stress
Beth Israel Deaconess Medical Center Integrated clinical environments
Boston Medical Center  Clinical systems integration
Boston University  Interoperability
Children’s Hospital of Boston  Simulation
Harvard Medical School Other programs
Newton–Wellesley Hospital  Biodetection and sepsis
Northeastern University  Biomaterials and tissue engineering
Partners HealthCare  Cardiovascular disease
VA Boston Healthcare System  Global health
 Inhalation technology
 Minimally invasive surgery
 Optical diagnostics




3.  Enabled funding: more than 60% 
generated follow-on funding. On 
average, every dollar invested by 
CIMIT yields an almost ninefold 
return in additional investment 
from government agencies, foun-
dations, companies, or private 
investors.
4.  Patents: more than 15% have at 
least one issued patent.
5.  Publications: more than 60% 
have published at least one peer-
reviewed article (resulting in 
more than 700 articles in total).
Hopefully, CIMIT, now in year 
12, is on the brink of establishing a 
translational-research and development 
model that is replicable and sustain-
able beyond the tenure of its present 
leadership.
conclusion
Based on the education provided by 
more than a dozen years of transla-
tional research in dermatology, three 
large experiments were started in order 
to study the best environments for hos-
pital-based multidisciplinary transla-
tional research.
The fact that the WCP is based on a 
single theme (biomedical photonics) 
is complemented by the clinical pull 
of C-4s, the versatility of light for both 
therapy and diagnosis, and technologi-
cal advances that make photomedicine 
possible in essentially every organ of the 
body. The WCP has transformed from a 
dermatology-only laboratory to a pow-
erful multispecialty center whose larg-
est project at present is cardiovascular 
imaging and treatment. In the domain 
of devices and procedures, CIMIT proj-
ects are usually initiated by clinicians 
based on unmet clinical needs, and 
facilitation is provided by a committed 
core of experts. Both the major driver 
and the major success of the CBRC 
have been a growing understanding of 
molecular biology relevant to skin. The 
garden is now very fertile for a strong 
pull by clinical needs in dermatology.
This report is confined to three 
Boston hospital–based multidisciplinary 
translational-research centers founded 
and directed by an individual MGH 
dermatologist. Applicability to global 
challenges and possibilities for multidis-
ciplinary translational research within 
and among industry, academia, and gov-
ernment may be limited. Furthermore, 
the experiments described here are still 
in progress. However, in the confines 
of the Boston and MGH academic plat-
form, there are lessons evolving:
1.  During initial launch, leader-
ship must be entirely (or mostly) 
committed to the success of the 
center itself. It works better if the 
leadership does not compete with 
the supported investigators for 
resources or academic rewards.
2.  To be effective, facilitation 
requires a broad spectrum of 
sophisticated expertise, and it 
must be highly individualized. 
For instance, CIMIT spends 
more than 25% of its funds on 
the full-time team that coaches 
each investigative team on topics 
such as protection of intellectual 
property, market surveys, com-
pliance and regulatory issues, 
protection of human and animal 
rights, and the basic principles 
of the scientific method. This 
powerful resource is quite 
different from administration, 
operations, and financing, 
which, combined, require less 
than 10% of the budget. All facil-
itation services and coaching 
must be done in collaboration 
with the institution’s licensing 
and technology offices.
3.  In our hands, “clinical pull” 
is much more effective than 
“technology push.” The applied 
research must be directed by a 
clinician.
4.  It requires large core funding to 
launch and stabilize a hospital-
based translational-research cen-
ter. Each of the centers described 
here required over $150 million 
over more than 10 years. CBRC 
core funding was provided by 
industry; WCP and CIMIT were 
eventually supported primarily 
by the Department of Defense.
5.  The most important factor is 
the people. It requires special 
people to act as “site min-
ers,” program leaders, C-4s, 
and facilitators. Supported 
investigators must have a rec-
ognizable blend of creativity, 
generosity, joy of collaboration, 
and passion to improve health 
care. Academic excellence is 
necessary, but not sufficient.
In all these explorations, I have been 
very fortunate to be surrounded by per-
sons far brighter and more skilled than 
I, and I have therefore managed to stay 
in training for more than 45 years. I am 
blessed and very grateful.
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